Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological MalignanciesAmin M Alousi, Jonathan E Brammer, Rima M Saliba, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Transplantation and Cellular Therapy|July 12, 2023
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell TransplantationFevzi F Yalniz, Uri Greenbaum, Oren Pasvolsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2013
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantationRohtesh S Mehta, Antonio Di Stasi, Borje S Andersson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 28, 2016
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaFleur M Aung, Benjamin Lichtiger, Gabriela Rondon, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological MalignanciesAmin M Alousi, Jonathan E Brammer, Rima M Saliba, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Transplantation and Cellular Therapy|July 12, 2023
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell TransplantationFevzi F Yalniz, Uri Greenbaum, Oren Pasvolsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2013
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantationRohtesh S Mehta, Antonio Di Stasi, Borje S Andersson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 28, 2016
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaFleur M Aung, Benjamin Lichtiger, Gabriela Rondon, et al.
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Pageof 15